Jinshi Biotech Awarded National "Specialized, Sophisticated, Distinctive, and Innovative" Little Giant Enterprise Certification

On September 2, 2024, the list of Jiangsu Province's sixth batch of specialized, refined, distinctive, and innovative "little giant" enterprises was announced, and Kingstron Bio was awarded the national-level specialized, refined, distinctive, and innovative "little giant" certification.

In 2011, the Ministry of Industry and Information Technology of China first proposed to vigorously promote the development of small and medium-sized enterprises towards the "specialized, refined, distinctive, and innovative" direction. In 2022, the term "specialized, refined, distinctive, and innovative" was first written into the Government Work Report. In 2024, the Third Plenary Session of the 20th Central Committee of the Communist Party of China adopted the Decision of the Central Committee of the Communist Party of China on Further Comprehensively Deepening Reforms and Promoting China's Modernization, which proposed to "build a mechanism to promote the growth and development of specialized, refined, distinctive, and innovative small and medium-sized enterprises."

"Little Giant" enterprises, as the highest level in the梯度cultivation of "specialized, refined, novel" enterprises, are located in the core areas of industrial foundations and key links of the industrial chain. They stand out in innovation capability, master core technologies, have high market share in细分markets, and demonstrate excellent quality and效益. They represent the core strength of high-quality中小enterprises.

Kingstron Bio was founded in 2012, bringing together numerous experts and doctors from the field of heart valves both domestically and internationally. Adhering to an integration of industry, academia, and research, and following an independent technological route, the company possesses core patented technologies that are industry-leading in valve production. In 2018, Kingstron Bio launched its first product: the Element Power Valve Annuloplasty Ring, which quickly became the top Chinese-produced product in its category due to the advantages of its third-generation semi-rigid physiological ring. From 2021 to 2022, Kingstron Bio successively introduced the Xilinbo Pericardial Bioprosthetic Heart Valve and the Yilit Pericardial Biopatch, both utilizing proprietary patented anti-calcification treatment technology for pericardium that leads the industry, combined with the latest advancements in valve mechanical design, achieving a quality comparable to the latest generation of imported products. In the future, Kingstron Bio will continue to provide multiple industry-leading products for Chinese heart disease patients and doctors, including a dry, pre-mounted transcatheter aortic valve system, a transcatheter mitral valve system, and vascular grafts, leveraging its strong R&D capabilities and long-term strategic planning.

Kingstron Bio will always adhere to the philosophy of "Caring for health, starting from the heart," and build on the foundation of being a “little giant” by continuing to deeply cultivate the field of structural heart disease. It aims to create more and better products for patients and doctors in China.